RIMADYL 50MG TABLETS FOR DOGS Аустралија - Енглески - APVMA (Australian Pesticides and Veterinary Medicines Authority)

rimadyl 50mg tablets for dogs

zoetis australia pty ltd - carprofen - oral tablet - carprofen anti-inflammatory-nonsteroidal active 50.0 mg/tb - musculoskeletal system - dog | bitch | castrate | puppy - analgesic | inflammatory joint disease | antipyretic | colic | muscle relaxant | non-infectious joint disease | sedative | spasmolytic

Elaprase Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

elaprase

pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml;   - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).

Xeomin Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

xeomin

pharmacy retailing (nz) ltd t/a healthcare logistics - botulinum toxin type a 100 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a - powder for injection - 100 units - active: botulinum toxin type a 100 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a excipient: albumin sucrose - xeomin is indicated in adults for the treatment of: · cervical dystonia · blepharospasm · spasticity of the upper limb · upper facial lines -glabellar frown lines -lateral periorbital lines (crow's feet) - horizontal forehead lines

Xeomin Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

xeomin

pharmacy retailing (nz) ltd t/a healthcare logistics - botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a - powder for injection - 50 units - active: botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a excipient: albumin sucrose - xeomin is indicated in adults for the treatment of: · cervical dystonia · blepharospasm · spasticity of the upper limb · upper facial lines -glabellar frown lines -lateral periorbital lines (crow's feet) - horizontal forehead lines

PREZISTA darunavir 800 mg tablet bottle Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

prezista darunavir 800 mg tablet bottle

janssen-cilag pty ltd - darunavir, quantity: 800 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - adult patients,prezista ( with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

PREZISTA darunavir 600mg tablets bottle Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

prezista darunavir 600mg tablets bottle

janssen-cilag pty ltd - darunavir, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; polyvinyl alcohol; macrogol 3350; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; sunset yellow fcf aluminium lake; titanium dioxide - adult patients,prezista ( with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.,paediatric patients,prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.